SCHEDULE: Vanguard Group Reports Zero Arcutis Biotherapeutics Stake

The Vanguard Group reports zero beneficial ownership in Arcutis Biotherapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 1 to Schedule 13G for Arcutis Biotherapeutics Inc. Common Stock.
• As of the event date of March 13, 2026, The Vanguard Group reports 0 shares beneficially owned, representing 0% of the class.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing for Arcutis Biotherapeutics Inc., as it primarily concerns an internal organizational change within The Vanguard Group's reporting structure, not a change in investment thesis or performance of the issuer.

Future Outlook

No forward-looking statements or guidance regarding Arcutis Biotherapeutics Inc.'s future performance or The Vanguard Group's future investment plans are provided in this filing.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that this filing reflects an internal operational change within The Vanguard Group's reporting structure rather than a direct investment decision or change in sentiment regarding Arcutis Biotherapeutics Inc. Such realignments can impact how institutional ownership is tracked across the market, potentially fragmenting reported holdings for large asset managers.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure for changes in beneficial ownership by a large institutional investor.
• The disaggregated reporting approach adopted by The Vanguard Group aligns with SEC guidance for complex asset management structures, allowing individual funds or divisions to report their holdings independently.

Stakeholder Impact

• Shareholders of Arcutis Biotherapeutics Inc. may observe a change in reported institutional ownership data from The Vanguard Group, as holdings will now be reported by individual subsidiaries rather than aggregated under the parent entity. This does not necessarily indicate a change in the underlying investment by Vanguard-managed funds.

Next Steps

• The Vanguard Group's subsidiaries and/or business divisions will now report their beneficial ownership of Arcutis Biotherapeutics Inc. securities separately.

Key Dates

Keywords

Arcutis Biotherapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Disaggregated Reporting